Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study-Reference-Cited by-同舟云学术

Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study

Published:2022-10 Issue:5 Volume:7 Page:100571
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Boni V.,Pistilli B.,Braña I.,Shapiro G.I.,Trigo J.,Moreno V.,Castellano D.,Fernández C.,Kahatt C.,Alfaro V.,Siguero M.,Zeaiter A.,Longo F.,Zaman K.,Antón A.,Paredes A.,Huidobro G.,Subbiah V.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference19 articles.

1. A systematic review of international guidelines and recommendations for the genetic screening, diagnosis, genetic counseling, and treatment of BRCA-mutated breast cancer;Forbes;Cancer Manag Res,2019

2. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium;Ford;Lancet,1994

3. BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis;Foulkes;Fam Cancer,2006

4. Update on PARP inhibitors in breast cancer;Zimmer;Curr Treat Options Oncol,2018

5. Lurbinectedin inactivates the Ewing sarcoma oncoprotein EWS-FLI1 by redistributing it within the nucleus;Harlow;Cancer Res,2016

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics and Safety of Lurbinectedin Administrated with Itraconazole in Cancer Patients: A Drug–Drug Interaction Study;Marine Drugs;2024-04-16

2. A Comprehensive Review on the Role of Lurbinectedin in Soft Tissue Sarcomas;Current Treatment Options in Oncology;2024-02

3. Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval ≥30 days and without central nervous metastases;Lung Cancer;2024-02

4. Impact of a Moderate CYP3A4 Inducer (Bosentan) on Lurbinectedin Pharmacokinetics and Safety in Patients with Advanced Solid Tumors: An Open-Label, Two-Way, Crossover, Phase Ib Drug–Drug Interaction Study;Pharmaceuticals;2024-01-30

5. Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid Tumours;European Journal of Cancer;2023-10